Nonogaki Ryo, Ota Hikaru, Takeuchi Jun, Nakano Yuyako, Sajiki Ai Fujita, Todoroki Takahito, Nakamura Koichi, Kaneko Hiroki, Nishiguchi Koji M
Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Ophthalmology, Nagoya University School of Medicine, 65 Tsurumai, Shouwa, Aichi, Japan.
Sci Rep. 2024 Dec 30;14(1):31951. doi: 10.1038/s41598-024-83473-6.
This study aimed to evaluate the changes in cytokine levels in the aqueous humor and factors of treatment resistance following intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration. A total of 32 eyes were analyzed before and after a single faricimab injection. Although the best-corrected visual acuity (BCVA) showed no significant improvement, the mean central retinal thickness decreased significantly by 73.7% (P < 0.01), and more than 90% of the eyes showed improvement in exudative changes 1 month after faricimab injection. Moreover, the aqueous humor concentrations of vascular endothelial growth factor (VEGF)-A, angiopoietin (Ang)-2, and placental growth factor considerably decreased 1 month after faricimab injection. Multivariate analyses adjusted for age, sex, BCVA, central choroidal thickness, and aqueous humor cytokines revealed that higher Ang-2 levels in the aqueous humor at baseline were associated with better treatment response to faricimab injection. These findings suggest that the dual inhibition of VEGF-A and Ang-2 by faricimab is effective in reducing exudative changes and that Ang-2 may serve as a potential biomarker for predicting faricimab treatment response.
本研究旨在评估初治的新生血管性年龄相关性黄斑变性患者玻璃体内注射法西单抗后房水中细胞因子水平的变化以及治疗抵抗因素。共对32只眼在单次注射法西单抗前后进行了分析。虽然最佳矫正视力（BCVA）无显著改善，但平均中央视网膜厚度显著降低了73.7%（P<0.01），且超过90%的眼在注射法西单抗1个月后渗出性改变有所改善。此外，注射法西单抗1个月后，房水中血管内皮生长因子（VEGF）-A、血管生成素（Ang）-2和胎盘生长因子的浓度显著降低。对年龄、性别、BCVA、中央脉络膜厚度和房水细胞因子进行校正的多变量分析显示，基线时房水中较高的Ang-2水平与对法西单抗注射的更好治疗反应相关。这些发现表明，法西单抗对VEGF-A和Ang-2的双重抑制在减少渗出性改变方面有效，且Ang-2可能作为预测法西单抗治疗反应的潜在生物标志物。
